Interview with Igor Kouznetsov, General Director, Euroservice
You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of…
Address: 107031, Москва, Трубная площадь, дом 2, Бизнес-центр ‘Неглинная Плаза’,Russia
Tel: +7 (495) 229-29-99
Web: http://www.roche.ru/portal/roche.ru
Roche’ subsidiary in Russia was opened in 1991 and since then the company’s biotechnological medicines for the treatment of cancer, severe virus infections, autoimmune inflammatory diseases and metabolic disorders are widely marketed in Russia. The headquarters are located in Moscow, with subsidiaries in Saint-Petersburg and Novosibirsk. Roche’s development of novel and highly effective medicines is the result of numerous clinical trials conducted by the company according to GCP (Good Clinical Practice) worldwide, including Russia. Clinical trials in Russia are performed in the context of long-term cooperation with major Russian research centers. The leaders among them are Russian N.N. Blokhin Oncology Scientific Center in Moscow, Prof. N.N. Petrov Cancer Research Institute in Saint-Petersburg, Republican Oncology Center and AIDS Center in Kazan and many others. Roche closely monitors the quality of both local trials and parts of multinational clinical projects conducted in Russia.
A large number of Roche’s medicines are included into the Federal Reimbursement List due to the Federal program of reimbursement of certain categories of citizens. The company is a Good Corporate Citizen and takes an active part in social healthcare projects and initiatives. Roche supports the Equal Right to Life program initiated by oncologists. The goal of the program is to implement modern technologies of cancer diagnostics and treatment into regional healthcare institutions and to provide equal opportunities to proper treatment to all patients regardless of their social status or location.
Additional information on Roche in Russia can be found at www.roche.ru
The Roche company was founded in 1896 in Basel, Switzerland. At present Roche has subsidiaries in 150 countries worldwide and employs over 80,000 people. The investment in research and development in 2010 was over 9 billion Swiss francs , with Group sales of 47,5 billion Swiss francs. Roche wholly owns Genentech, USA and has a majority stake in Chugai Pharmaceutical, Japan.
Roche is one of the leading global pharmaceutical companies and the world’s leader in in vitro diagnostics and tissue-based cancer diagnostics. Personalised medicine strategy allows Roche to develop novel medicines and diagnostics tools that save and prolong patients’ lives significantly improving their quality of life.
You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of…
In spring of 2010, Protek became the first Russian wholesaler to enter the public stock market, raising $400Mn in the biggest Russian IPO since 2007. You offered the IPO directly…
PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better…
Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you…
You worked for ten years at Schering-Plough—one of the largest pharmaceutical companies in the world. In February of last year, you joined Merz Pharma, a much smaller player. Some may…
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to…
Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have…
Petrovax has always been an innovative company, making it quite unique in Russia where the domestic industry is predominantly comprised of generics manufacturers. How would you describe the positioning of…
After a long history in Philips, this is your first tenure as a regional CEO. Having been at this position for less than a year, what are your impressions of…
You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed,…
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
See our Cookie Privacy Policy Here